Recruiting

New Biomarkers for Non-Invasive Diagnosis and Prognosis of Non-Alcoholic Fatty Liver Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to identify and validate new soluble biomarkers for liver fibrosis, which can be used in non-invasive clinical tests for the diagnosis and prognosis of Non-Alcoholic Fatty Liver Disease.

What is being collected

Data Collection

Collected from today forward - Prospective
DNA Samples
Who is being recruted

Body Weight+17

+ Diabetes Mellitus

+ Diabetes Mellitus, Type 2

From 18 to 65 Years
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: September 2015
See protocol details

Summary

Principal SponsorUniversity of Trieste
Study ContactSilvia Palmisano, MD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 22, 2015

Actual date on which the first participant was enrolled.

This study focuses on Non-alcoholic Fatty Liver Disease (NAFLD), a common condition linked to unhealthy lifestyles, such as overeating and lack of physical activity. Currently, there are no effective medicines for NAFLD, and the best way to prevent or improve it is through a healthier lifestyle. However, many people struggle to adapt to these changes. The study aims to identify new biomarkers, or indicators, of NAFLD. These biomarkers could lead to the development of non-invasive tests for early detection of the disease, which could motivate individuals to change their lifestyle. The study is particularly interested in finding biomarkers that can diagnose and predict the progression of NAFLD. The study will be conducted in three phases. First, the researchers will use computer programs to analyze a large amount of genetic and protein data to identify potential biomarkers. Then, they will collect blood and liver samples from patients undergoing bariatric surgery, and measure the levels of these potential biomarkers. Finally, they will correlate the levels of these biomarkers with the severity of the disease, as determined by blood tests, liver biopsy, and imaging techniques. The study plans to enroll 62 patients and will take approximately 12 months to complete.

Official TitleIdentification of New Biomarkers in the Diagnosis and Prognosis of Non-alcoholic Fatty Liver Disease and Correlation With Ultrasound and Elastographic Findings
NCT06098417
Principal SponsorUniversity of Trieste
Study ContactSilvia Palmisano, MD
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

500 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Body WeightDiabetes MellitusDiabetes Mellitus, Type 2Digestive System DiseasesEndocrine System DiseasesFatty LiverFibrosisLiver CirrhosisLiver DiseasesMetabolic DiseasesNutrition DisordersNutritional and Metabolic DiseasesObesityPathologic ProcessesSigns and SymptomsPathological Conditions, Signs and SymptomsOvernutritionGlucose Metabolism DisordersOverweightNon-alcoholic Fatty Liver Disease

Criteria

Inclusion Criteria: BMI\> 35 Eligible for bariatric surgery according to the current international guidelines (IFSO guidelines) Exclusion Criteria: * Patients affected by active liver viral infection * Patient alcohol or drug addicted * Incompetent patients

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Silvia Palmisano

Trieste, ItalyOpen Silvia Palmisano in Google Maps
Recruiting
One Study Center
New Biomarkers for Non-Invasive Diagnosis and Prognosis of Non-Alcoholic Fatty Liver Disease | PatLynk